Arbutus Biopharma Corporation

DB:I9DN Stock Report

Market Cap: €611.6m

Arbutus Biopharma Valuation

Is I9DN undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of I9DN when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate I9DN's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate I9DN's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for I9DN?

Key metric: As I9DN barely has revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for I9DN. This is calculated by dividing I9DN's market cap by their current book value.
What is I9DN's PB Ratio?
PB Ratio6.2x
BookUS$106.89m
Market CapUS$646.17m

Price to Book Ratio vs Peers

How does I9DN's PB Ratio compare to its peers?

The above table shows the PB ratio for I9DN vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average1.8x
FYB Formycon
1.5x31.5%€857.2m
BIO3 Biotest
2x29.3%€1.3b
HPHA Heidelberg Pharma
3x-33.0%€105.8m
MDG1 Medigene
0.9x11.0%€17.4m
I9DN Arbutus Biopharma
6.2x11.7%€646.2m

Price-To-Book vs Peers: I9DN is expensive based on its Price-To-Book Ratio (6.2x) compared to the peer average (1.8x).

Price to Book Ratio vs Industry

How does I9DN's PB Ratio compare vs other companies in the DE Biotechs Industry?

3 CompaniesPrice / BookEstimated GrowthMarket Cap
V9Z Aceragen
0.1xn/aUS$3.12m
V9Z Aceragen
0.1xn/aUS$2.18m
O7P NeuBase Therapeutics
0.1xn/aUS$1.39m
No more companies available in this PB range
I9DN 6.2xIndustry Avg. 2.4xNo. of Companies3PB00.61.21.82.43+
3 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: I9DN is expensive based on its Price-To-Book Ratio (6.2x) compared to the European Biotechs industry average (2.4x).

Price to Book Ratio vs Fair Ratio

What is I9DN's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

I9DN PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio6.2x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate I9DN's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst I9DN forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€3.17
€4.98
+56.8%
18.9%€6.70€3.80n/a5
Nov ’25€3.43
€4.60
+34.2%
21.8%€6.44€3.69n/a5
Oct ’25€3.41
€4.56
+33.8%
21.1%€6.30€3.67n/a5
Sep ’25€3.40
€4.21
+23.8%
10.6%€4.58€3.66n/a5
Aug ’25€3.43
€4.24
+23.5%
10.9%€4.62€3.66n/a5
Jul ’25€2.81
€4.06
+44.7%
11.1%€4.63€3.68n/a5
Jun ’25€2.99
€4.09
+36.6%
11.2%€4.65€3.72n/a5
May ’25€2.54
€4.07
+60.3%
11.1%€4.63€3.69n/a5
Apr ’25€2.36
€4.05
+72.1%
11.4%€4.62€3.64n/a5
Mar ’25€2.54
€4.05
+59.9%
11.4%€4.62€3.64n/a5
Feb ’25€2.26
€4.26
+89.1%
16.9%€5.49€3.64n/a5
Jan ’25€2.27
€4.30
+89.7%
17.4%€5.60€3.73n/a5
Dec ’24€1.94
€4.30
+121.7%
17.4%€5.60€3.73n/a5
Nov ’24€1.70
€4.29
+152.5%
17.3%€5.59€3.73€3.435
Oct ’24€1.85
€4.29
+132.2%
17.3%€5.59€3.73€3.415
Sep ’24€1.83
€4.90
+167.2%
14.8%€5.44€3.63€3.405
Aug ’24€2.00
€4.93
+146.7%
14.4%€5.51€3.69€3.435
Jul ’24€2.02
€4.96
+145.7%
14.1%€5.49€3.73€2.815
Jun ’24€2.30
€4.93
+114.7%
15.0%€5.52€3.64€2.995
May ’24€2.23
€4.92
+120.7%
14.8%€5.47€3.65€2.545
Apr ’24€2.70
€4.99
+84.6%
14.9%€5.56€3.69€2.365
Mar ’24€2.58
€5.09
+97.4%
15.1%€5.70€3.77€2.545
Feb ’24€2.70
€5.09
+88.4%
15.1%€5.70€3.77€2.265
Jan ’24€2.12
€5.01
+136.3%
15.0%€5.62€3.72€2.275
Dec ’23€2.19
€5.22
+138.1%
14.8%€5.83€3.88€1.945
Nov ’23€2.33
€6.22
+166.5%
30.8%€9.26€3.85€1.705

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

Teva Pharmaceutical Industries

US$18.8b

Develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally.

TEV

US$15.65

7D

-3.7%

1Y

76.2%

Collegium Pharmaceutical

US$1.0b

A specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management.

354

US$29.60

7D

5.7%

1Y

27.6%

Pharming Group

€491.5m

A biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally.

PHGN

€0.70

7D

-0.7%

1Y

-34.1%